In contrast, using a VAF threshold of 1%, none of the patients in our study cohort were detected with CH alterations from the tumor tissues, precluding the need for additional sequencing of PBCs when adopting the tumor-informed approach. The gene discussed is C4B; the disease is neoplasm.